H3.3-K27M neoantigen vaccine

The H3.3-K27M neoantigen vaccine is an investigational peptide-based cancer vaccine (biologic) designed to treat diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas harboring the H3.3-K27M mutation. This mutation, a lysine 27-to-methionine substitution in the histone H3.3 variant, is a critical driver present in over 70% of DIPG cases. The vaccine consists of a synthetic neoantigen peptide corresponding to this mutation, which is administered alongside the adjuvant poly-ICLC (a TLR3 agonist). The mechanism of action involves the uptake of the peptide by antigen-presenting cells, which then present the neoantigen to the immune system to activate mutation-specific CD4+ and CD8+ T-cell responses. These activated T cells are intended to target and eliminate tumor cells expressing the H3.3-K27M protein. It is currently being evaluated in the Phase I ENACTING clinical trial in combination with standard-of-care radiotherapy.

Other names

Histone H3.3-K27M Neoantigen Vaccine TherapyEnhanced Histone H3.3-K27M Neoantigen VaccineH3.3-K27M peptide vaccineH-3.3-K27M peptide vaccineH 3.3-K27M peptide vaccine